Valens GroWorks Rebrands to The Valens Company

Valens GroWorks rebrands to 'The Valens Company' to reflect the "next phase" for the company.

Valens GroWorks Corp. (TSXV: VGW), a vertically integrated provider of industry-leading extraction products and services; including a diverse suite of extraction methodologies, next-generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab, announced today that it is rebranding to 'The Valens Company,' and effective at market open on December 19, 2019, will trade on the TSXV under the ticker VLNS.

The rebrand solidifies the Company's focus on the development and manufacturing of innovative cannabis products and marks its commitment to enter high-value international markets in 2020.

The introduction of our new parent company brand, The Valens Company, on the eve of Cannabis 2.0, is a reflection of our growth and transformation over the past few yearsTyler Robson, CEO of Valens

"Valens is best known as a leader in extraction, but we are much more than that. After years of research, product development, technology acquisitions and more, we are thrilled to introduce the next phase of growth for our company," Robson concluded.

This phase will solidify our position as an international leader in the end-to-end development and manufacturing of cannabinoid-based products. As we look ahead to 2020, we are energized by the tremendous opportunities in the market and excited to go into the new year as The Valens Company."

Strategic Clarity on Company's Position as Global Leader in End-to-End Development of Cannabis and Hemp-based Products

The Company is also refining its branding to better reflect its position as a global leader in cannabis product development and manufacturing. While Valens' iconic logo will remain unchanged, effective at the start of trading on December 19, 2019, the Company's stock ticker will be "VLNS" on the TSXV (with its ticker changing on the OTCQX once final regulatory approvals are received).   Valens also expects to formally change its name in due course.

Evolution in Expertise: From Extraction to Full Product Development

Having already established itself as the leader in extraction, the rebrand marks The Valens Company's evolution to a cannabinoid-based product development and manufacturing company, strategically positioned to capitalize on both "Cannabis 2.0" in Canada as well as a wealth of international opportunities. Valens has been preparing heavily for the new wave of legalization by building a portfolio of innovative manufacturing and end-product technologies to help its customers offer customized user experiences and differentiate their products in the market.  In a short period of time, Valens has become a one-stop shop for licensed producers as well as CPG and pharma companies in providing the broadest product and service offerings in the Canadian market.

The Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and expects to have more innovative products coming to the Canadian market in 2020.

A Leader in Safe, Reliable Oil Derivatives to Support 2.0 Rollout for Customers

As the industry develops domestically and internationally, Valens has prioritized acquiring and developing safe and differentiated technologies in order to facilitate high quality oil outputs for delivery methods such as vaping and ingestible products. In the case of beverages and edibles, for example, this includes the international rights to a leading emulsion technology, SōRSE, which the Company believes will transform the way consumers experience ingested cannabis. For vaping oils, Valens has proven to be an important ally to its clients in this highly monitored sector, utilizing its breadth of extraction and formulation techniques to create, cannabis-derived oils that not only meet the health standards required but allow customers to differentiate its offerings and experiences for their targeted consumers.

GMP Product Capabilities

Valens has entered into a multi-year manufacturing agreement with a Health Canada licensed party that provides the Company with additional licensed capacity to support its overwhelming demand for white label product development services. Under the terms of the agreement, an initial 5,000 square feet has been allocated to Valens operations with a total of up to 50,000 square feet being made available subject to the counterparty receiving the required Health Canada licence amendment. The licensed space is cGMP certified in Canada and provides a second channel for exportation of Valens GMP certified products early in 2020. The Company expects to utilize the space in a variety of ways as needed, including beverages, edibles, topicals and storage.

Commitment to Enter High-Value International Markets

With over 100 years of combined extraction experience and years of extraction equipment and product formulation advancements under its belt, The Valens Company has developed significant intellectual property and built a global reputation for high quality products that are in demand in legal markets around the world. Simultaneously, the Company has been building its domestic state-of-the-art facilities, including proprietary equipment and technologies, with the goal to effectively transplant similar operations to high-value international markets starting in 2020.

Valens Farms Joint Venture Terminated

In conjunction with Valens' rebrand and strategic evolution away from cultivation, the Company has terminated its joint venture agreement with Kosha Projects Inc. ("Kosha") to create the Valens Farms facility originally announced on April 11, 2018.

Subsequent to entering into the arms length joint venture agreement with Kosha, one of the partners joined the board of directors of the Company, creating a related party relationship.  As a result, in connection with the termination of the joint venture, the Company engaged an independent advisor, to review certain costs incurred by Kosha, its subcontractors and Valens on the project.  The objective of this review was to provide information to the Company for it to determine that the final settlement in the amount of $931,194 for the termination of the agreement included only those costs that were incurred on the project.  Based on the independent review process followed, the board of directors (the Company's director associated with Kosha abstaining), determined that the final settlement amount was reasonable.

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *